Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Endocyte , a biopharmaceutical company developing treatments for oncological and inflammatory diseases, jumped as much as 10% after receiving an analyst upgrade.
So what: Endocyte shares rallied by double digits after brokerage firm R.W. Baird upped its rating on the company to "outperform" from "neutral" and boosted its price target to $13 from $9. Specific to the upgrade, Baird noted that Endocyte's primary early-stage pipeline is further along than it had previously thought and figures it could boast some promising drug candidates.
Now what: I've said it before and I'll say it again -- don't get caught up in the hoopla often involved with one-day price swings caused by analyst upgrades and downgrades, as they rarely have any bearing on your long-term investing thesis. As for Endocyte, a lot of its true success is riding on the outcome of a late-stage trial in the U.S. and a European Medicines Agency decision on Vintafolide for ovarian cancer. The drug is actually licensed to Merck , but the royalties could go a long way to establishing Endocyte as a reputable -- and potentially profitable -- biopharmaceutical company.
Craving more input? Start by adding Endocyte to your free and personalized watchlist so you can keep up on the latest news with the company.
Can Merck beat the patent cliff?
This titan of the pharmaceutical industry stumbled into 2013 and continues to battle patent expirations and pipeline problems. Is Merck still a solid dividend play, or should investors be looking elsewhere? In a new premium research report on Merck, The Fool tackles all of the company's moving parts, its major market opportunities, and reasons to both buy and sell. To find out more click here to claim your copy today.
The article Why Endocyte Shares Soared originally appeared on Fool.com.
Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.